Howard Heidi Carmen, Borry Pascal
Centre for Biomedical Ethics and Law, Katholieke Universiteit Leuven, Kapucijnenvoer 35, Box 7001, 3000, Leuven, Belgium,
J Community Genet. 2012 Apr;3(2):105-12. doi: 10.1007/s12687-011-0062-0. Epub 2011 Sep 6.
Over the last couple of years, many commercial companies, the majority of which are based in the USA, have been advertising and offering direct-to-consumer (DTC) genetic testing services outside of the established health care system, and often without any involvement from a health care professional. In the last year, however, a number of DTC genetic testing companies have changed their provision model such that consumers must now contact a health care professional before being able to order the genetic testing service. In discussing the advent of this new model of service provision, this article also reviews the ethical and social issues surrounding DTC genetic testing and addresses the potential motivations for change, some barriers to achieving truly appropriate medical supervision and the present reality of DTC genetic testing for some psychiatric and neurological disorders. Since the advent of these commercial activities, critics have pointed a finger at the lack of medical supervision surrounding these services. The discussion herein, however, reveals how difficult it may be, despite the addition of a physician, to actually achieve adequate medical supervision within the present context of DTC genetic testing.
在过去几年里,许多商业公司(其中大部分位于美国)一直在既定医疗保健系统之外宣传并提供直接面向消费者(DTC)的基因检测服务,而且通常没有医疗保健专业人员的参与。然而,在去年,一些DTC基因检测公司改变了其服务提供模式,现在消费者必须先联系医疗保健专业人员,才能订购基因检测服务。在讨论这种新的服务提供模式的出现时,本文还回顾了围绕DTC基因检测的伦理和社会问题,探讨了变革的潜在动机、实现真正适当医疗监督的一些障碍以及针对某些精神和神经疾病的DTC基因检测的现状。自从这些商业活动出现以来,批评者一直指责这些服务缺乏医疗监督。然而,本文的讨论揭示了,尽管增加了医生,但在目前DTC基因检测的背景下,实际实现充分的医疗监督可能有多困难。